Daye Peak Announces Quality Award for Mayor of Huangshi City
Release time:
2022-01-17
News from our newspaper 2021 12# April 31 to 2022 1# October 6 , the official website of Huangshi Municipal Market Supervision and Administration Bureau carried out a one-week publicity on the enterprises (organizations) to be awarded for the 7th Huangshi Mayor Quality Award and the enterprises (organizations) to be awarded for the nomination award. Daye Peak, as the enterprises to be awarded, passed the publicity smoothly.
Huangshi Mayor's Quality Award is the highest quality award in Huangshi City. It has been awarded since2010 and is held every 2 years. Currently, 11 enterprises have won the award. The award has a high evaluation standard and strict examination. It has gone through the examination of application materials, the defense of the general manager, and the on-site evaluation of experts to the enterprise. After layers of screening, a shortlist is formed, and then the award is finally determined through comprehensive evaluation and publicity. Since
Daye Peak was put into production, it has always attached importance to internal quality control. By strengthening source management, process optimization, production process control and after-sales service, "Peak" brand cement has formed a high popularity and influence in Hubei market. Since applying for the Huangshi Mayor Quality Award, the company has further checked and filled the gaps, made sufficient preliminary preparations, and received unanimous praise from the expert group during the review process.successfully passed the public announcement this time, which means that daye peak will become the second cement enterprise in Huangshi area and the first cement enterprise in daye city to win the mayor's quality award of Huangshi city. The person in charge of
Daye Peak said that by participating in the selection, Daye Peak has fully tapped its own advantages, and also saw the strengths of others and found its own shortcomings in the process of comparison and screening with brother companies. The future growth of the enterprise will play a positive role in promoting. In the future work, Daye Peak will continue to improve, and strive to become the benchmark of Huangshi enterprises and the benchmark of the cement industry, to achieve high quality and sustainable development.
(Chen Cuihong
Hong Wenbo)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31